%0 Journal Article
%T The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus
%A Dave L. Dixon
%A Salvatore Carbone
%J Archive of "Cardiovascular Diabetology".
%D 2019
%R 10.1186/s12933-019-0869-2
%X Renal actions of SGLT2 inhibitors. SGLT2, sodium glucose co-transporter 2; SGLT1, sodium glucose co-transporter
%K Diabetes mellitus
%K Major adverse cardiovascular event
%K Sodium glucose co-transporter 2 inhibitor
%K Canagliflozin
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540565/